KIORA PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
KIORA PHARMACEUTICALS, INC. (KPRX) reported Increase (Decrease) in Accounts Receivable of -$431.38 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$452.87K, a 141.92% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $21.48K, a 97.08% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $309.54K.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$1.20M, a 372.47% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $921.57K, a 53.29% increase from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $601.20K.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2015 was $907.50K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$452.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$431.38K 10-Q · filed 2026-08-07 | -$121.84K derived: sum of 3 quarters · filed 2026-08-07 | -$1.33M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $21.48K 10-Q · filed 2026-05-08 | $331.03K derived: sum of 2 quarters · filed 2026-05-08 | -$873.77K derived: sum of 3 quarters · filed 2026-05-08 | $206.65K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $309.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$895.25K derived: sum of 2 quarters · filed 2026-03-25 | $185.17K derived: sum of 3 quarters · filed 2026-08-07 | $921.57K 10-K · filed 2026-03-25 |
| 2025-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$124.38K derived: sum of 2 quarters · filed 2026-08-07 | $612.03K 10-Q · filed 2025-11-07 | -$570.25K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.82M 10-Q · filed 2026-08-07 | $634.55K derived: sum of 3 quarters · filed 2026-08-07 | $1.08M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $736.41K 10-Q · filed 2026-05-08 | -$445.87K derived: sum of 2 quarters · filed 2026-05-08 | -$3.69K derived: sum of 3 quarters · filed 2026-05-08 | $1.15M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$740.10K derived: sum of 2 quarters · filed 2026-03-25 | $411.29K derived: sum of 3 quarters · filed 2026-03-25 | $601.20K 10-K · filed 2026-03-25 |
| 2024-09-30 | $442.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.59M derived: sum of 2 quarters · filed 2025-11-07 | $1.78M 10-Q · filed 2025-11-07 | $1.78M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.34M 10-Q · filed 2025-08-08 | $1.34M derived: sum of 3 quarters · filed 2025-08-08 | $1.34M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $189.90K 10-Q · filed 2025-05-09 | $189.90K derived: sum of 2 quarters · filed 2025-05-09 | $189.90K derived: sum of 3 quarters · filed 2025-05-09 | $189.90K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $0.00 10-K · filed 2025-03-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |||
| 2015-12-31 | $907.50K 10-K · filed 2016-03-30 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |